FME Stock Chart & Stats
CHF36.28
-CHF75.28(-100.00%)
At close: 4:00 PM EDT
CHF36.28
-CHF75.28(-100.00%)
Day’s Range― - ―
52-Week RangeCHF31.91 - CHF97.00
Previous CloseN/A
Volume400.00
Average Volume (3M)0.00
Market Cap
CHF10.07B
Enterprise ValueCHF21.51K
Total Cash (Recent Filing)CHF1.45B
Total Debt (Recent Filing)CHF10.96B
Price to Earnings (P/E)12.2
Beta-0.17
Next Earnings
Nov 03, 2026EPS Estimate
0.99Next Dividend Ex-DateN/A
Dividend Yield3.6%
Share Statistics
EPS (TTM)3.32
Shares Outstanding268,564,640
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.89
Price to Sales (P/S)0.60
P/FCF Ratio6.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF35.18Price Target Upside-3.04% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering11
EPS Forecast (FY)3.8
Revenue Forecast (FY)CHF18.15B
Bulls Say, Bears Say
Bulls Say
Revenue And EBIT ImprovementThe sharp top-line acceleration and wider operating margin indicate improved business execution and operating leverage. If sustained, this combination can strengthen earnings capacity across FME’s care delivery and dialysis products businesses.
Solid Cash GenerationStrong operating and free cash flow provide funding for maintenance investment, business needs, and shareholder distributions. Consistent conversion of earnings into cash supports financial resilience even if operating conditions become less favorable.
Moderate And Improving LeverageLower leverage than in prior years improves balance-sheet flexibility and reduces financing risk. This gives FME more capacity to support its global clinic and products operations while managing reimbursement, regulatory, and healthcare-demand pressures.
Bears Say
Mid-Level Net MarginsDespite stronger EBIT performance, limited net profitability leaves less earnings protection against reimbursement pressure, labor costs, manufacturing expenses, and other operating volatility. Margin improvement may therefore not fully translate into durable bottom-line growth.
Declining Equity CushionA shrinking equity base weakens financial capacity relative to the scale of operations and leaves less protection against future losses or restructuring needs. Although leverage is improving, the reduced cushion remains a structural balance-sheet constraint.
Softer Free Cash Flow MomentumStable cash generation is positive, but declining free cash flow momentum suggests that recent operating improvements have not yet produced sustained cash expansion. Continued softness could limit investment capacity or reduce flexibility for distributions and debt management.
FME FAQ
What was Fresenius Medical Care AG & Co. KGaA’s price range in the past 12 months?
Fresenius Medical Care AG & Co. KGaA lowest stock price was CHF31.91 and its highest was CHF97.00 in the past 12 months.
What is Fresenius Medical Care AG & Co. KGaA’s market cap?
Fresenius Medical Care AG & Co. KGaA’s market cap is CHF10.07B.
When is Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date?
Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date is Nov 03, 2026 which is in 68 days.
How were Fresenius Medical Care AG & Co. KGaA’s earnings last quarter?
Fresenius Medical Care AG & Co. KGaA released its earnings results on Aug 03, 2026. The company reported CHF1.052 earnings per share for the quarter, beating the consensus estimate of CHF1 by CHF0.052.
Is Fresenius Medical Care AG & Co. KGaA overvalued?
According to Wall Street analysts Fresenius Medical Care AG & Co. KGaA’s price is currently Overvalued.
Does Fresenius Medical Care AG & Co. KGaA pay dividends?
Fresenius Medical Care AG & Co. KGaA pays a Annually dividend of CHF1.39 which represents an annual dividend yield of 3.6%. See more information on Fresenius Medical Care AG & Co. KGaA dividends here
What is Fresenius Medical Care AG & Co. KGaA’s EPS estimate?
Fresenius Medical Care AG & Co. KGaA’s EPS estimate is 0.99.
How many shares outstanding does Fresenius Medical Care AG & Co. KGaA have?
Fresenius Medical Care AG & Co. KGaA has 268,564,640 shares outstanding.
What happened to Fresenius Medical Care AG & Co. KGaA’s price movement after its last earnings report?
Fresenius Medical Care AG & Co. KGaA reported an EPS of CHF1.052 in its last earnings report, beating expectations of CHF1. Following the earnings report the stock price went up 1.907%.
Which hedge fund is a major shareholder of Fresenius Medical Care AG & Co. KGaA?
Currently, no hedge funds are holding shares in CH:FME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius Medical Care AG & Co. KGaA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.62%
12-Months-Change
Fundamentals
Return on Equity
3.60%
Trailing 12-Months
Asset Growth
<0.01%
Trailing 12-Months
Company Description
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
FME Stock 12 Month Forecast
Average Price Target
CHF35.18
▼(-3.04% Downside)
Technical Analysis
CompuGroup Medical
―
Draegerwerk AG & Co. KGaA
―
Fresenius SE & Co. KGaA
―
MEDICLIN
―
RHON-KLINIKUM AG
―










